CMMB vs IOVA: stock comparison

Chemomab Therapeutics Ltd. American Depositary Share

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Open CMMB dashboard ↗

Iovance Biotherapeutics, Inc. Common Stock

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It develops lifileucel for treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001, an antibody cytokine engrafted protein for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Open IOVA dashboard ↗

CMMB vs IOVA

Compare the businesses

Chemomab Therapeutics Ltd. American Depositary Share

Iovance Biotherapeutics, Inc. Common Stock

Sign in to keep comparing stocks